{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000015","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.768845+00:00","generated_at":"2026-06-04T15:12:09.091725+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elicio raises $6.0M via pre-funded warrants sale to board-member entity GKCC, LLC","bullets":["Private placement of pre-funded warrants for 1,032,702 shares at $5.81 each; gross proceeds ~$6.0M.","Warrants exercisable at $0.01/share subject to 19.99% beneficial ownership cap unless stockholder approval obtained.","Purchaser GKCC, LLC is controlled by a member of Elicio's board of directors.","Closing expected March 19, 2024; proceeds for pipeline advancement and working capital.","Company must file resale registration statement with SEC by June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000015","json":"https://secwatch.observer/filing/0001601485-24-000015.json","markdown":"https://secwatch.observer/filing/0001601485-24-000015.md","text":"https://secwatch.observer/filing/0001601485-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000015/0001601485-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000015/angn-20240318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:12:09.091725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"252c64e62a23cbd4f1e01281eacc8b8583fc0cac","claim":"Elicio Therapeutics, Inc. entered into Subscription Agreement with GKCC, LLC valued at approximately $6.0 million (effective 2024-03-18).","evidence_excerpt":"On March 18, 2024, Elicio Therapeutics, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with GKCC, LLC (the “Purchaser”), an entity controlled by a member of the board of directors of the Company, providing for the issuance and sale by the Company to the Purchaser of pre-funded warrants (the “Pre-Funded Warrants\") to purchase up to 1,032,702 shares of common stock, par value $0.01 per share, of the Company (“Common Stock”), at a purchase price per Pre-Funded Warrant of $5.81 (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000015/0001601485-24-000015-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"GKCC, LLC"},{"label":"Value","value":"approximately $6.0 million"},{"label":"Effective","value":"2024-03-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}